NASDAQ:XLO Xilio Therapeutics (XLO) Stock Price, News & Analysis $9.00 0.00 (0.00%) As of 09/4/2026 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOwnershipSEC Filings About Xilio Therapeutics Stock (NASDAQ:XLO) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Xilio Therapeutics alerts:Sign Up Key Stats Today's Range$8.81▼$9.2350-Day Range$8.31▼$9.5852-Week Range$6.47▼$12.74Volume7,643 shsAverage Volume10,732 shsMarket Capitalization$59.22 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview Xilio Therapeutics is a clinical‐stage biotechnology company focused on the discovery and development of tumor‐targeted cytokine therapeutics for the treatment of cancer. The company leverages a proprietary platform to design pro‐drug versions of potent immune‐modulating cytokines, enabling local activation of immune responses within the tumor microenvironment while limiting systemic exposure and toxicity. The company’s lead programs utilize engineered interleukin‐12 (IL‐12) and interleukin‐2 (IL‐2) molecules fused to tumor‐binding antibodies or peptide ligands. These candidates are designed to selectively accumulate in tumor tissues and activate local innate and adaptive immunity. Xilio has advanced multiple assets into early‐phase clinical studies, evaluating safety, pharmacokinetics and preliminary signals of anti‐tumor activity across various solid tumor types. The pipeline also includes additional preclinical programs that apply the same targeting and activation principles to other cytokine payloads. Founded in 2018 and headquartered in Cambridge, Massachusetts, Xilio Therapeutics has assembled a management team with deep experience in oncology drug development and biologics engineering. The company conducts its clinical trials primarily in the United States and Europe and collaborates with academic and industry partners to accelerate the translation of its pipeline candidates into potential cancer therapies. Xilio remains committed to advancing its modular cytokine platform to address unmet needs in immuno‐oncology.AI Generated. May Contain Errors. Read More Xilio Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks4th Percentile Overall ScoreXLO MarketRank™: Xilio Therapeutics scored higher than 4% of companies evaluated by MarketBeat, and ranked 879th out of 910 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingSell Consensus RatingXilio Therapeutics has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageXilio Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Xilio Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Book Value per Share RatioXilio Therapeutics has a P/B Ratio of 1.23. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Xilio Therapeutics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted6.93% of the float of Xilio Therapeutics has been sold short.Short Interest Ratio / Days to CoverXilio Therapeutics has a short interest ratio ("days to cover") of 31.63, which indicates bearish sentiment.Change versus previous monthShort interest in Xilio Therapeutics has recently decreased by 0.93%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldXilio Therapeutics does not currently pay a dividend.Dividend GrowthXilio Therapeutics does not have a long track record of dividend growth. News and Social Media2.3 / 5News Sentiment0.67 News SentimentXilio Therapeutics has a news sentiment score of 0.67. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.79 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Xilio Therapeutics this week, compared to 1 article on an average week. Company Ownership0.9 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Xilio Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders7.45% of the stock of Xilio Therapeutics is held by insiders.Percentage Held by Institutions54.29% of the stock of Xilio Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Xilio Therapeutics' insider trading history. Receive XLO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Xilio Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. XLO Stock News HeadlinesAgios Pharmaceuticals (NASDAQ:AGIO) and Xilio Therapeutics (NASDAQ:XLO) Head to Head SurveySeptember 4 at 2:15 AM | americanbankingnews.comXilio Therapeutics Grants Inducement Stock Options to New Employees Under 2022 PlanSeptember 2, 2026 | quiverquant.comQThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying out up to $1,152 a month to regular investors - no mining stocks, no options, no physical metal required. Chief Income Strategist Tim Plaehn calls it a breakthrough strategy that transforms gold's rally into reliable monthly payouts. The next distribution is just days away.September 7 at 1:00 AM | Investors Alley (Ad)Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)September 2, 2026 | globenewswire.comXilio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Pipeline and Business UpdatesAugust 12, 2026 | globenewswire.comXilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)July 6, 2026 | markets.businessinsider.comXilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)July 6, 2026 | globenewswire.comXilio Therapeutics, Inc.: Xilio Therapeutics Appoints Ben Harshbarger as Chief Legal OfficerJune 29, 2026 | finanznachrichten.deSee More Headlines XLO Stock Analysis - Frequently Asked Questions How have XLO shares performed this year? Xilio Therapeutics' stock was trading at $8.9628 at the start of the year. Since then, XLO shares have increased by 0.4% and is now trading at $9.00. How were Xilio Therapeutics' earnings last quarter? Xilio Therapeutics, Inc. (NASDAQ:XLO) issued its quarterly earnings results on Thursday, August, 13th. The company reported ($0.33) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.59) by $0.26. The business had revenue of $18.69 million for the quarter, compared to analysts' expectations of $12.72 million. Xilio Therapeutics had a negative trailing twelve-month return on equity of 71.99% and a negative net margin of 34.06%. When did Xilio Therapeutics' stock split? Shares of Xilio Therapeutics reverse split on the morning of Friday, March 13th 2026.The 1-14 reverse split was announced on Thursday, March 12th 2026. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, March 12th 2026. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. When did Xilio Therapeutics IPO? Xilio Therapeutics (XLO) raised $125 million in an initial public offering on Wednesday, October 20th 2021. The company issued 7,353,000 shares at a price of $16.00-$18.00 per share. Who are Xilio Therapeutics' major shareholders? Xilio Therapeutics' top institutional shareholders include Stonepine Capital Management LLC (3.43%), GSA Capital Partners LLP (0.21%) and BlackRock Inc. (0.13%). Insiders that own company stock include Gilead Sciences, Inc, Venture Fund Xi LP Atlas, Rene Russo, James Samuel Shannon, Christopher James Frankenfield and Kevin M Brennan. View institutional ownership trends. How do I buy shares of Xilio Therapeutics? Shares of XLO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Xilio Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Xilio Therapeutics investors own include PayPal (PYPL), Achilles Therapeutics (ACHL), JPMorgan Chase & Co. (JPM), AT&T (T), United Microelectronics (UMC), Adverum Biotechnologies (ADVM) and Atai Beckley (ATAI). Company Calendar Last Earnings8/13/2026Today9/07/2026Next Earnings (Estimated)11/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (15m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 XLO's financial health is in the Yellow zone, according to TradeSmith. XLO has been in this zone for over 15 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:XLO CIK1840233 Webwww.xiliotx.com Phone857-524-2466FaxN/AEmployees70Year Founded2015Profitability EPS (Trailing Twelve Months)($1.64) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$35.04 million Net Margins-34.06% Pretax Margin-34.06% Return on Equity-71.99% Return on Assets-20.43% Debt Debt-to-Equity RatioN/A Current Ratio4.25 Quick Ratio4.25 Sales & Book Value Annual Sales$43.77 million Price / Sales1.35 Cash FlowN/A Price / Cash FlowN/A Book Value$7.31 per share Price / Book1.23Miscellaneous Outstanding Shares6,580,000Free Float6,090,000Market Cap$59.22 million OptionableNot Optionable Beta-0.14 Social Links 7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.Get This Free Report This page (NASDAQ:XLO) was last updated on 9/7/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Xilio Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Xilio Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
